RxDoctor Payments Data

David Kassel, MD

Interventional Cardiology · Mesa, AZNPI 1861460792

Payments from drug & device makers

$1,450in general payments, 2019–2025

Across 31 payments — averaging $46.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$457
  • Abiomed$245
  • AstraZeneca$233
  • Actelion Pharmaceuticals US, Inc.$225
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$105
  • Medtronic$67
  • plus $118 from 4 others

What the payments were for

  • Food & beverage$1,450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,450 in reported general payments places this provider in the 10th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$590,238
Medicare patients
1,323
Services billed
5,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban590$734,057
EntrestoSacubitril/Valsartan107$143,337
XareltoRivaroxaban60$93,625
Repatha SureclickEvolocumab103$89,102
FarxigaDapagliflozin Propanediol30$33,093
Praluent PenAlirocumab19$13,229
BrilintaTicagrelor15$12,491
Dabigatran EtexilateDabigatran Etexilate Mesylate29$12,260
Metoprolol Succinate831$11,931
Atorvastatin Calcium660$6,536
Rosuvastatin Calcium413$6,172
Losartan Potassium422$4,611
Ranolazine ErRanolazine41$4,537
Ezetimibe159$4,270
Potassium Chloride204$4,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$233$45,58445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →